<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 2 - Mims</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page1.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../index.html#p=2">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 2 - Mims</div>
        <div id="content-top2">P. 2</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../index.html#p=2"><img src="../thumb/2.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>NEW!
                                                  S3 REAPTAN
                             Introducing



                                         The clone of
                                         T he clone of          S3



                          =                            EFFECTIVE BP lowering

                                                       24 HR BP control
                                                       PROVEN CV* protection

                                                       WELL reimbursed
                                                        Fully reimbursed on all Discovery plans
                                                        (except Keycare), all BestMed plans and all GEMs plans.
        *CV: Cardiovascular
        Reference Safety Information - October 2019. What is Reaptan ®  indicated for: Reaptan ®  is indicated for the treatment of hypertension in patients already stabilised with perindopril and
        amlodipine at equivalent dosages. Treatment of hypertension in patients uncontrolled on either perindopril or amlodipine monotherapy. Do not use Reaptan ®  in case of:* • Hypersensitivity
        to the active substances, or to any other ACE-inhibitor or to dihydropyridines derivatives, or to any of the excipients, • Hereditary /idiopathic angioedema, history of angioedema associated
        with previous ACE-inhibitor therapy, • Second and third trimesters of pregnancy, • Concomitant use of Reaptan ®  with aliskiren-containing products in patients with diabetes mellitus or renal
        impairment (GFR &lt; 60 ml/min/1,73 m), • Severe hypotension, shock, including cardiogenic shock, • Obstruction of the outﬂ ow-tract of the left ventricle (e.g. high grade aortic stenosis), •
        Haemodynamically unstable heart failure after acute myocardial infarction. • Concomitant use with sacubitril/valsartan. #   • Extracorporeal treatments leading to contact of blood with
        negatively charged surfaces. #  • Signiﬁ cant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney.  #  • Porphyria. What are the important identiﬁ ed risks and
        the main undesirable effects that may occur with Reaptan ® ?* Hypersensitivity/Angioedema: • Angioedema of the face, extremities, lips, mucous membranes, tongue, glottis and/or
        larynx has been reported rarely in patients treated with ACE inhibitors, including perindopril. • In such cases: discontinue Reaptan ® , initiate and continue appropriate monitoring until complete
        resolution of symptoms has occurred. In those instances where swelling was conﬁ ned to the face and lips the condition generally resolved without treatment, although antihistamines have
        been useful in relieving symptoms. • Angioedema associated with laryngeal oedema may be fatal. • Where there is involvement of the tongue, glottis or larynx, likely to cause airway
        obstruction, emergency therapy should be administered promptly. This may include the administration of adrenaline and/or the maintenance of a patent airway. • Patients with a history of
        angioedema unrelated to ACE-inhibitor therapy may be at increased risk of angioedema while receiving an ACE-inhibitor. • Intestinal angioedema has rarely been reported. Patients presented
        with abdominal pain (with or without nausea and vomiting): in some cases there was not prior facial engioedema and C-1 esterase levels were normal. • Due to increased risk of angioedema,
        sacubitril/valsartan must not be initiated until 36 hours after taking the last dose of perindopril therapy. Perindopril therapy must not be started until 36 hours after the last dose of sacubitril/
        valsartan. Concomitant use of other NEP inhibitors (e.g. racecadotril) and ACE-inhibitos may also increase the risk of angioedema.  #  • Concomitant use of mTOR inhibitors may be at increased
        risk for angioedema. • Frequency: uncommon (≥ 1/1 000 to &lt; 1/100). Neutropenia/Agranulocytosis/Thrombocytopenia: • Perindopril should be used with extreme caution in patients
        with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing
        impaired renal function. If perindopril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection (e.g.
        sore throat, fever). • Frequency: very rare (&lt; 1/10 000). Hypotension: • More likely to occur in patients who have been volume-depleted (e.g. by diuretic therapy, dietary salt restriction,
        dialysis, diarrhoea or vomiting) or who have severe renin-dependent hypertension. • In patients at high risk of symptomatic hypotension, with ischaemic heart or cerebrovascular disease, blood
        pressure, renal function and serum potassium should be monitored closely. • Frequency: common (≥ 1/100 to &lt; 1/10). Hyperkalaemia: • Risk factors for the development of hyperkalemia:
        renal insufﬁ ciency, worsening of renal function, age (&gt; 70 years), diabetes mellitus, intercurrent events, in particular dehydratation, acute cardiac decompensation, metabolic acidosis, and
        concomitant use of potassium-sparing diuretics, potassium supplements or potassium containing salt substitutes; or other drugs associated with increases in serum potassium (e.g. heparin,
        co-trimoxazole also known as trimethoprim/sulphamethoxazole).  #  • If concomitant use of perindopril and any of the above mentioned agents is deemed appropriate, they should be used with
        caution and with frequent monitoring of serum potassium. • Frequency: uncommon (not known (≥ 1/1 000 to &lt; 1/10). The other common undesirable effects of Reaptan ®  are somnolence,
        dizziness, headache (especially at the beginning of treatment), dysgeusia, paraesthesia, visual disturbances (including diplopia), tinnitus, vertigo, palpitations, ﬂ ushing, dyspnoea, cough,
        abdominal pain, nausea, vomiting, dyspepsia, change in bowel habits, diarrhoea, constipation, pruritis, rash, exanthema, joint swelling (ankle swelling), muscle spasms, fatigue and asthenia.
        What are the other warnings or precautions associated with the use of Reaptan ® ?* • Anaphylactoid reaction during - low-density lipoprotein (LDL) apheresis with dextran sulphate:
        rarely, patients have experienced life threatening anaphylactoid reactions, temporarily withhold treatment prior to exams. - desensitisation treatment (e.g. Hymenoptera venom): Temporarily
        withhold treatment prior to exams. These reactions reappeared upon inadvertent rechallenge. • Renovascular hypertension: increased risk of hypotension and renal insufﬁ ciency when patient
        with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with ACE-inhibitors Diuretics may be a contributory factor. Loss of renal function may occur
        (minor changes in serum creatinine) even in patients with unilateral renal artery stenosis.  #  • Dual blockade of the renin-angiotensin-aldosterone system (RAAS): concomitant use of ACE-
        inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS is
        therefore not recommended. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy. • Primary aldosteronism: use not
        recommended in patients with primary hyperaldosteronism (not responding medication acting through inhibition of the renin-angiotensin system).  #  • Pregnancy: ACE-inhibitors should not
        be initiated during pregnancy. When pregnancy is diagnosed, stop treatment with ACE-inhibitors immediately and, if appropriate, start alternative therapy. • Mitral valve stenosis/obstruction
        in the outﬂ ow of the left ventricle (e.g. aortic stenosis, hypertrophic cardiomyopathy), cardiac failure: use with caution.• Renal impairment: monitor potassium and creatinine; individual dose
        titration with the monocomponents recommended if Clcr &lt; 60 ml/min. In patients with renal artery stenosis, blood urea and creatinine may increase; with renovascular hypertension, risk of
        severe hypotension and renal insufﬁ ciency. Renal failure: amlodipine is not dialysable. • Hepatic failure: rarely, ACE-inhibitors have been associated with a syndrome that starts with cholestatic
        jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. Stop treatment if jaundice or marked elevations of hepatic enzymes. Impaired hepatic function: slow dose
        titration and careful monitoring if severe hepatic impairment. • Black people: ACE-inhibitors may be less effective and cause a higher rate of angioedema than in non-black. • Cough: non-
        productive. • Surgery/Anaesthesia: stop treatment one day prior to surgery. • Diabetic patients: monitor glycaemia during ﬁ rst month. • Hypertensive crisis: safety and efﬁ cacy of amlodipine
        has not been established. • Elderly patients: dosage increase with care. • Galactose intolerance/glucose-galactose malabsorption/Lapp lactase deﬁ ciency: should not be taken. • Lithium/
        Potassium-sparing medicines/Potassium supplements/Dantrolene: not recommended.  # Pending
        References: Bahl V, et al.  J Hypertens; 2010:e98. STRONG. Bahl VK, et al. Am J Cardiovasc Drugs 2009;9:135-142. PEARL-ABPM Nagy VL. Clin Drug Inves 2013; DOI 10.1007/s40261-013-0086-9. SYMBIO
        Hatala R, et al. Clin Drug Inves 2012;32(9): 603-612. CREOLE Poulter N, et al. N Eng J Med 2019; DOI: 10.1056/NEJMoa1901113. ASCOT-BPLA Lancet 2005;366:895-906. ASCOT Legacy Published online
        Aug 26, 2018 http://dx.doi.org/10.1016/S0140-6736(18)31776-8. Discovery Chronic Illness Beneﬁt List January 2020. www.discovery.co.za. Medikredit Scheme Protocols January 2020. www.medikredit.

        co.za. Medscheme Comprehensive PMB Formulary and MPL January 2020. www.medscheme.co.za. REAPTAN ®  package insert approved by the Medicines Regulatory Authority, June 2019. COVERAM ®
        package insert approved by the Medicines Regulatory Authority, Feb 2018. Mediscor, accessed January 2020. www.mediscor.net.
        S3 Coveram ®  5 mg /5 mg tablets: Perindopril arginine 5 mg + Amlodipine 5 mg (as besilate) Reg. No. 43/7.1.3/0933
        S3 Coveram ®  5 mg/10 mg tablets: Perindopril arginine 5 mg + Amlodipine 10 mg (as besilate) Reg. No. 43/7.1.3/0934
        S3 Coveram ®  10 mg/5 mg tablets: Perindopril arginine 10 mg + Amlodipine 5 mg (as besilate) Reg. No. 43/7.1.3/0935
        S3 Coveram ®  10 mg/10 mg tablets: Perindopril arginine 10 mg + Amlodipine 10 mg (as besilate) Reg. No. 43/7.1.3/0936.
        For full prescribing information refer to latest Professional Information approved by the Regulatory Authority, 21 February 2018
        NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE: SERVIER LABORATORIES SOUTH AFRICA (Pty) Ltd.
        Reg. No. 72/14307/07. Building Number 4, Country Club Estate, 21 Woodlands Drive, Woodmead 2191. PO Box 930, Rivonia 2128,
        Republic of South Africa. Tel: +27 (0)861 700 900. Fax: +27 (0)11 525 3401.
        S3 Reaptan ®  5 mg /5 mg tablets: Perindopril arginine 5 mg + Amlodipine 5 mg (as besilate) Reg. No. 43/7.1.3/0929.
        S3 Reaptan ®  5 mg/10 mg tablets: Perindopril arginine 5 mg + Amlodipine 10 mg (as besilate) Reg. No. 43/7.1.3/0930.
        S3 Reaptan ®  10 mg/5 mg tablets: Perindopril arginine 10 mg + Amlodipine 5 mg (as besilate) Reg. No. 43/7.1.3/0931.
        S3 Reaptan ®  10 mg/10 mg tablets: Perindopril arginine 10 mg + Amlodipine 10 mg (as besilate) Reg. No. 43/7.1.3/0932.
        For full prescribing information refer to latest Professional Information approved by the Regulatory Authority, June 2019.
        NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE: BIOGARAN SOUTH AFRICA (Pty) Ltd.
        Reg. No. 2001/011749/07. Building Number 4, Country Club Estate, 21 Woodlands Drive, Woodmead, 2191. P.O. Box 2962,
        Rivonia, 2128, Republic of South Africa. TEL: +27(0)11 525 3448 FAX: +27(0) 866 465 144. 1920/1/Reap/Advert</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page1.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page1.html">1</a>&nbsp;&nbsp;&nbsp;<a href="page2.html">2</a>&nbsp;&nbsp;&nbsp;<a href="page3.html">3</a>&nbsp;&nbsp;&nbsp;<a href="page4.html">4</a>&nbsp;&nbsp;&nbsp;<a href="page5.html">5</a>&nbsp;&nbsp;&nbsp;<a href="page6.html">6</a>&nbsp;&nbsp;&nbsp;<a href="page7.html">7</a>
             </td>
             <td width="35%"><a href="page3.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page3.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
